2. Signaling Pathways
  3. PROTAC
  4. Molecular Glues

Molecular Glues

Molecular Glues

Related Products

PDF 0.26 MB

Protein degradation agents based on the ubiquitin-proteasome pathway include a part of molecular glues. Molecular glues are a class of small molecule compounds that can induce or stabilize the interaction between proteins. If one of the protein is ubiquitin ligase, molecular glue can cause another protein to undergo ubiquitin modification and degradation through the proteasome pathway, which is similar to PROTAC. However, these molecules are classified as ligand for E3 ligase as functional molecules in subsequent classification. Older drugs, thalidomide, lenalidomide, and pomalidomide, together with CC-90009 and CC-92480 reported later all belong to this category.

Molecular Glues Related Products (172):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14658B
    (R)-Thalidomide 2614-06-4 99.80%
    (R)-Thalidomide ((R)-(+)-Thalidomide) is the R-enantiomer of Thalidomide. (R)-Thalidomide has psychomotor stabilizing properties.
    (R)-Thalidomide
  • HY-A0003A
    Lenalidomide hydrochloride 1243329-97-6
    Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator. Lenalidomide hydrochloride (CC-5013 hydrochloride) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hydrochloride (CC-5013 hydrochloride) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
    Lenalidomide hydrochloride
  • HY-10984S2
    Pomalidomide-d4 1416575-78-4
    Pomalidomide-d4 is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<
    Pomalidomide-d<sub>4</sub>
  • HY-169347
    dCK1α-2 3085297-83-9
    dCK1α-2 is an orally active CK1α molecular glue degrader that targets p53 pathway-related targets. dCK1α-2 exhibits anti-tumor efficacy in mouse models and can increase the expression of p53-related genes..
    dCK1α-2
  • HY-156730A
    KT-333 ammonium 2839758-34-6
    KT-333 ammonium (Compound A) is a molecular glues that degrades STAT3 protein. KT-333 ammonium mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 ammonium has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 ammonium can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL).
    KT-333 ammonium
  • HY-B0579S5
    Cyclosporin A-d12
    Cyclosporin A-d12 (Cyclosporine A-d12) is deuterium labeled Cyclosporin A. Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A also inhibits CD11a/CD18 adhesion.
    Cyclosporin A-d<sub>12</sub>
  • HY-156730B
    KT-333 diammonium 2502186-80-1
    KT-333 diammonium is a molecular glues that degrades STAT3 protein. KT-333 diammonium mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 diammonium has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 diammonium can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL).
    KT-333 diammonium
  • HY-100507A
    Avadomide hydrochloride 1398053-45-6
    Avadomide hydrochloride (CC 122 hydrochloride) is the hydrochloride form of Avadomide (HY-100507). Avadomide hydrochloride is an orally active cereblon modulator. Avadomide hydrochloride modulates cereblon E3 ligase activity, inhibits NF-κB pathway, arrests the cell cycle at G1 phase, and thus induces apoptosis in cancer cell PDAC. Avadomide hydrochloride exhibits potent antitumor and immunomodulatory activities.
    Avadomide hydrochloride
  • HY-163811
    BRD9 Degrader-4 3024541-39-4
    BRD9 Degrader-4 (BRD9c), a bifunctional molecular glue, is a potent BRD9 degrader with a DC50 of ≤25 nM. BRD9 Degrader-4 has anti-cancer effects.
    BRD9 Degrader-4
  • HY-169343
    FIZ1 degrader 1 1957235-62-9
    FIZ1 degrader 1 (compound 1) is an IMiD-based molecular glue degrader targeting FIZ1.
    FIZ1 degrader 1
  • HY-162533
    GSPT1 degrader-4 3034764-32-1
    GSPT1 degrader-4 (3) is a GSPT1 molecule glue (DC50 of 25.4 nM), with an IC50 of 39 nM for CAL51 proliferation.
    GSPT1 degrader-4
  • HY-170518
    IKZF-IN-1
    IKZF-IN-1 (Compound I) is the molecular glue, that degrades ikaros zinc finger family (IKZF) IKZF 1/2/3/4, and can be used as an immunomodulator in research of cancer and viral infections.
    IKZF-IN-1
  • HY-170953
    QXG-6442
    QXG-6442 is a CK1α Molecular Glue Degrader. QXG-6442 exhibits CK1α degradation potency with a DC50 of 5.7 nM and a Dmax of 90%. QXG-6442 induces antiproliferative effects in MOLM-14 cell line.
    QXG-6442
  • HY-172770
    KMG-1068
    KMG-1068 (Compound 4a), a molecular glue, is a GSPT1/2 degrader. KMG-1068 effectively induces the CRBN-dependent degradation of GSPT1/2 by binding to the IMiD binding site on CRBN, facilitating the formation of a ternary complex with GSPT1/2. KMG-1068 is promising for research of cancers.
    KMG-1068
  • HY-146184
    CCT373567 2378853-67-7
    CCT373567 is a potent molecular glue degrader of transcriptional repressor BCL6, with an IC50 of 2.9 nM. CCT373567 exhibits antiproliferative activity.
    CCT373567
  • HY-153802A
    Antitumor agent-100 hydrochloride 2841750-53-4
    Antitumor agent-100 (compound A6) hydrochloride is an orally potent apoptosis inducer and molecular gel targeting PDE3A-SLFN12 (IC50: 0.3 μM) with antitumor activity. Antitumor agent-100 hydrochloride binds to the PDE3A enzyme pocket to recruit and stabilize SLFN12, thereby preventing protein translation and leading to apoptosis.
    Antitumor agent-100 hydrochloride
  • HY-172930
    PVTX-405 2991023-13-1
    PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC50  of  0.7 nM and a Dmax of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC50 of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn391V C57BL/6 mice.
    PVTX-405
  • HY-172931
    DEG-35 2734910-37-1
    DEG-35 is a CRBN-dependent, dual IKZF2 and CK1α molecule glue degrader, with DC50 values of 1.4 nM and 4.4 nM for CK1α and IKZF2, respectively. DEG-35 activates the p53 apoptosis pathway. DEG-35 can be used in the research for Acute Myeloid Leukemia (AML).
    DEG-35
  • HY-A0003S2
    Lenalidomide-13C5,15N
    Lenalidomide-13C5,15N is 15N and 13C labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
    Lenalidomide-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N
  • HY-163813
    AR Degrader-2 3023359-76-1
    AR Degrader-2 (Compound 2) is a molecular glue that degrades androgen receptor (AR) with a DC50 of 0.3-0.5 μM in cell VCaP.
    AR Degrader-2